Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.

Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, Baisley K, Tanton C, Hayes RJ, Marshak JO, Gladden RG, Koelle DM.

J Clin Microbiol. 2010 Oct;48(10):3496-503. doi: 10.1128/JCM.01263-10. Epub 2010 Aug 11.

2.

Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.

Kim HN, Wang J, Hughes J, Coombs R, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Fuchs J, Eshleman SH, Khaki L, McMahon MA, Siliciano RF, Wald A, Celum C.

J Infect Dis. 2010 Sep 1;202(5):734-8. doi: 10.1086/655662.

3.

Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.

McNicholl JM, Leelawiwat W, Whitehead S, Hanson DL, Evans-Strickfaden T, Cheng CY, Chonwattana W, Mueanpai F, Kittinunvorakoon C, Markowitz L, Dunne EF.

Int J STD AIDS. 2017 Mar;28(4):372-379. doi: 10.1177/0956462416650123. Epub 2016 Jul 10.

4.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

5.

Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L.

J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.

6.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

7.

Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.

LeGoff J, Weiss HA, Gresenguet G, Nzambi K, Frost E, Hayes RJ, Mabey DC, Malkin JE, Mayaud P, Belec L.

AIDS. 2007 Jul 31;21(12):1569-78.

PMID:
17630552
8.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

9.

Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.

Tobian AA, Grabowski MK, Serwadda D, Newell K, Ssebbowa P, Franco V, Nalugoda F, Wawer MJ, Gray RH, Quinn TC, Reynolds SJ; Rakai Health Sciences Program.

J Infect Dis. 2013 Sep 1;208(5):839-46. doi: 10.1093/infdis/jit252. Epub 2013 Jun 28.

10.

Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.

Mayaud P, Legoff J, Weiss HA, Grésenguet G, Nzambi K, Bouhlal H, Frost E, Pépin J, Malkin JE, Hayes RJ, Mabey DC, Bélec L; ANRS 1212 Study Group.

J Infect Dis. 2009 Jul 15;200(2):216-26. doi: 10.1086/599991.

PMID:
19530940
11.

Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.

Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, Belec L, Stevens W, Rees H, Mayaud P.

AIDS. 2009 Feb 20;23(4):461-9. doi: 10.1097/QAD.0b013e32831db217.

12.

Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.

Andersen-Nissen E, Chang JT, Thomas KK, Adams D, Celum C, Sanchez J, Coombs RW, McElrath MJ, Baeten JM.

Sex Transm Dis. 2016 Dec;43(12):761-764.

13.

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group.

N Engl J Med. 2007 Feb 22;356(8):790-9.

14.

A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.

Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, Robinson NJ, Bassett MT, Wilson D, Brown DW, Hayes RJ.

Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153. Epub 2008 Aug 6.

PMID:
18684855
15.

Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.

Fife KH, Mugwanya K, Thomas KK, Baeten JM, Celum C, Bukusi E, de Bruyn G, Mujugira A, Vwalika B, Wald A, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 May 15;213(10):1573-8. doi: 10.1093/infdis/jiv765. Epub 2015 Dec 23.

PMID:
26704611
16.

Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients.

Mitterreiter JG, Titulaer MJ, van Nierop GP, van Kampen JJ, Aron GI, Osterhaus AD, Verjans GM, Ouwendijk WJ.

PLoS One. 2016 May 12;11(5):e0155531. doi: 10.1371/journal.pone.0155531. eCollection 2016.

17.

HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.

Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

AIDS. 2009 Feb 20;23(4):479-83. doi: 10.1097/QAD.0b013e328326ca62.

18.

Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.

Henao-Martínez AF, Weinberg A, Waldman WJ, Levi ME.

J Clin Virol. 2012 Jul;54(3):276-8. doi: 10.1016/j.jcv.2012.02.026. Epub 2012 Mar 31.

PMID:
22465339
19.

Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.

Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L.

J Infect Dis. 2002 Dec 15;186(12):1718-25. Epub 2002 Nov 22.

PMID:
12447756
20.

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.

Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T, Balira R, Knight L, Hambleton I, Le Goff J, Belec L, Hayes R; HSV trial team; Steering and Data Monitoring Committees.

N Engl J Med. 2008 Apr 10;358(15):1560-71. doi: 10.1056/NEJMoa0800260. Epub 2008 Mar 12. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

Supplemental Content

Support Center